FY2026 EPS Estimate for Kura Oncology Raised by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at HC Wainwright boosted their FY2026 earnings estimates for Kura Oncology in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($3.19) per share for the year, up from their previous forecast of ($3.39). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.81) EPS, FY2027 earnings at ($2.16) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($1.86) EPS.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The business had revenue of $22.84 million for the quarter, compared to analyst estimates of $24.94 million.

Several other analysts also recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Deutsche Bank set a $24.00 price objective on Kura Oncology in a research report on Wednesday, October 14th. Morgan Stanley set a $24.00 price objective on Kura Oncology in a report on Monday, August 24th. JPMorgan Chase & Co. began coverage on Kura Oncology in a research report on Thursday, October 1st. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, UBS Group set a $24.00 target price on Kura Oncology in a research report on Thursday. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.88.

Kura Oncology Trading Down 3.9%

KURA opened at $7.43 on Friday. The stock has a market capitalization of $682.67 million, a P/E ratio of -2.25 and a beta of 0.56. The company has a current ratio of 3.60, a quick ratio of 4.71 and a debt-to-equity ratio of 0.07. Kura Oncology has a 12 month low of $6.75 and a 12 month high of $13.90. The firm’s fifty day simple moving average is $10.28 and its 200 day simple moving average is $9.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Kura Oncology during the 2nd quarter worth about $115,286,000. Dimensional Fund Advisors LP raised its holdings in shares of Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after purchasing an additional 348,127 shares during the period. Bank of America Corp DE lifted its stake in Kura Oncology by 46.1% in the 1st quarter. Bank of America Corp DE now owns 1,230,131 shares of the company’s stock valued at $10,001,000 after purchasing an additional 388,003 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Kura Oncology in the 2nd quarter valued at about $10,927,000. Finally, Pale Fire Capital SE grew its holdings in Kura Oncology by 89.6% during the first quarter. Pale Fire Capital SE now owns 857,474 shares of the company’s stock worth $6,971,000 after purchasing an additional 405,229 shares during the period.

Insider Buying and Selling

In related news, insider Teresa Bair sold 8,442 shares of the firm’s stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.50, for a total value of $88,641.00. Following the completion of the transaction, the insider directly owned 187,002 shares of the company’s stock, valued at approximately $1,963,521. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 28,802 shares of the business’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $309,621.50. Following the transaction, the insider owned 141,095 shares in the company, valued at approximately $1,516,771.25. The trade was a 16.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 153,881 shares of company stock worth $1,708,183 in the last quarter. 7.60% of the stock is owned by company insiders.

Top Kura Oncology Stories

Investors following KURA have been watching these stories:

• Positive Sentiment: Kura said it expects to receive $25 million in funding, which could add financial flexibility. Funding announcement
• Positive Sentiment: Third-quarter results highlighted 53% growth in KOMZIFTI revenue and progress on pipeline plans for 2027, potential commercial and development catalysts. Q3 results and pipeline plans
• Negative Sentiment: Brookline lowered its Q4 2026 EPS estimate, from a loss of $0.89 to $0.97 per share. Its estimate remains more pessimistic than HC Wainwright’s $0.81-per-share loss forecast, underscoring uncertainty around near-term expenses.

Kura Oncology Company Profile

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.